Joah Pharmaceutical, 21.13% ↑ Amid Rising Trend of Anthelmintics (Fenbendazole, etc.) Theme
On the 22nd, the anthelmintic (including Fenbendazole) theme rose by 3.45% compared to the previous day, showing strength, while Joa Pharmaceutical, which is attracting attention as a related stock, surged by 21.13% compared to the previous day. Joa Pharmaceutical is known as a pharmaceutical company specializing in drugs for liver disease treatment.
[Graph] Price changes of major stocks in the anthelmintic (including Fenbendazole) theme
According to the analysis by Thinkpool Robo Algorithm RASSI, Joa Pharmaceutical’s quant financial score is 22.08 points, with higher growth and stability scores than the average of other stocks related to anthelmintics (including Fenbendazole), but its quant financial ranking was only 6th out of 7 stocks. On the other hand, Aliko Pharmaceutical ranked 1st in quant financial ranking with higher growth, stability, and profitability scores compared to other stocks.
[Table] Top stocks by financial score within the theme
※ The quant financial score is the result of analysis by the robo algorithm based on each company’s sales growth rate, equity growth rate, debt ratio, current ratio, ROA, ROE, etc.
※ This article was generated in real-time by an article automatic generation algorithm jointly developed by Asia Economy and the financial AI specialist Thinkpool.
Hot Picks Today
"Not Everyone Can Afford This: Inside the World of the True Top 0.1% [Luxury World]"
- "Sold Out Everywhere" The Surprising Story of the 'Purple Gold' Philippine Yam That Has Captivated the World [Delicious Stories]
- While All Eyes Were on Samsung and Hynix, This Company Surged 50% to New Highs in Four Days [Weekend Money]
- "Now Our Salaries Are 10 Million Won a Month" Record High... Semiconductor Boom Drives Performance Bonuses at Major Electronic Component Firms
- Experts Already Watching Closely..."Target Price Set at 970,000 Won" Only Upward Momentum Remains [Weekend Money]
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.